Topics & People

Predicted by Dave Ricks to be the next major area for pharmaceutical breakthroughs, citing that they account for 40% of human suffering globally and current treatments are often inadequate.

National Institutes of Health, criticized for not funding a third-party investigation.

The application of artificial intelligence to analyze patient data, track skin lesions, and improve health outcomes.

A widespread societal issue exacerbated by poor physical health and digital distraction.

The massive substance abuse epidemic driving the visible street crises in Los Angeles.

A strategy where companies, particularly in China, analyze a filed patent to reverse-engineer a similar chemical structure that behaves similarly but falls outside the patent's legal scope. This is a significant threat to biotech innovation.

The venture capital market for biotechnology, which has plummeted from a peak of ~$20 billion to ~$5 billion a year in new investments. Dave Ricks describes the current market as a 'dumpster fire', making it difficult for new biotech firms to get funding.

Research and Development is the primary focus for Eli Lilly's capital allocation, with the company spending 25% of its sales ($14.2 billion this year) to create the next generation of medicines.

The strategic deployment of financial resources towards infrastructure, R&D, and acquisitions.

A major topic of discussion concerning the high cost of GLP-1 drugs. Eli Lilly is committed to reducing the price over time while balancing the need to fund future R&D, stating they expect single-digit deflation in the category over time.

A significant issue facing successful drugs like GLP-1s, with a large gray market, particularly involving peptide synthesis in China, producing unauthorized and potentially unsafe copies.

The original medical condition for which GLP-1 drugs were developed. Eli Lilly's first GLP-1 drug was a twice-a-day injection for diabetes launched in 2006.